Pulmonary mycoses. New concepts and new therapy.
The pathogenic and opportunistic fungi that commonly infect the human respiratory system cause diseases such as histoplasmosis, blastomycosis, aspergillosis, and invasive candidiasis. The increase in the incidence and severity of mycotic infections due to more aggressive immunosuppressive therapy and the spread of acquired immunodeficiency syndrome (AIDS) has had an impact on diagnosis and treatment of these conditions. Several therapeutic agents are currently available or undergoing clinical trials in the treatment of the pulmonary mycoses; among the agents with the greatest potential usefulness are the oral imidazoles, ketoconazole, itraconazole, and fluconazole.
George
R B
RB
Department of Medicine, Louisiana State University Medical Center, Shreveport 71130-3932.
D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy; D001759:Blastomycosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
D000935:Antifungal Agents